Serum VEGF as a significant marker of treatment response in Hodgkin lymphoma

Pediatric Hematology and Oncology

Volumn 24, Issue 2, 2007, Pages 111-115

  Arush, M Weyl Ben ^a   Barak, A Ben ^a   Maurice, S ^b   Livne, E ^b  

^a MEYER CHILDREN S HOSPITAL   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Angiogensis; Hodgkin lymphoma; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HODGKIN DISEASE; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; TREATMENT RESPONSE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HODGKIN DISEASE; HUMANS; MALE; NEOPLASM STAGING; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; REMISSION INDUCTION; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34247121880     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010601052381     Document Type: Article

References (19)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst.. 1990;82:4-6.
2. Kondo S, Asano M, Matsuo K, et al. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta. 1994;1221:211-214.
3. Yamamoto Y, Toi M, Kondo S, et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res. 1996;2:821-826.
4. Kumar H, Heer K, Lee WP, et al. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res. 1998;4:1279-1285.
5. Poon RTP, Ng IOL, Lau C, et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg. 2001;233:227-235.
6. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non Hodgkin's lymphoma. Blood.. 1997;90:3167-3172.
7. Bertolini F, Paolucci M, Peccatori F, et al. Angiogenic growth factors and endostatin in non Hodgkin's lymphoma. Br J Haematol. 1999;106:504-509.
8. Salven P, Orpana A, Teerenhovi L, et al. Simulatneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single institution study of 200 patients. Blood. 2000;96:3712-3718.
9. Mainou-Fowler T, Angus B, Miller S, et al. Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL). Leuk Lymphoma. 2006;47:223-230.
10. Tabone MD, Landman-Parker J, Arcil B. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?. Clin Cancer Res.. 2001;7:538-543.
11. Pavlakovic H, Von Schutz V, Rossler J, et al. Quantification of angiogenesis stimulators in children with solid malignancies. Int J Cancer. 2001;92:736-760.
12. Ben Arush MW, Schenzer P, Maurice S. Serum vascular endothelial growth factor as a significant marker of treatment response in pediatric malignancies. Pediatr Hematol Oncol. 2005;22:513-524.
13. Donaldson SS, Hudson MM, Lamborn RK, et al. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. J Clin Oncol. 2002;20:3081-3087.
14. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348:2386-2395.
15. Doussis-Anagnostopoulou AI, Talks LK, Turley H, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed- Sternberg cells in Hodgkin's disease. J Pathol. 2002;197:677-683.
16. Foss HD, Araujo I, Demel G, et al. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J Pathol. 1997;183:44-50.
17. Agarwal B, Naresh KN. Re: Doussis-Anagnostopoulou, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed- Sternberg cells in Hodgkin's disease. J Pathol. 2002;197:677-683.
18. J Pathol. 2003;201:334-335.
19. Giles F J, Vose JM, Do KA, et al. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res.. 2004;28:595-604.